Literature DB >> 7673963

Pretarsal application of botulinum toxin for treatment of blepharospasm.

M Aramideh1, B W Ongerboer de Visser, J W Brans, J H Koelman, J D Speelman.   

Abstract

The response to botulinum toxin type A was compared after two injection techniques in 45 patients with blepharospasm. Initially, patients were treated according to a triple injection technique; two injections into the upper eyelid and one injection into the lower eyelid. Subsequently, without altering the dose, the same patient group received two further injections into the pretarsal portion of the orbicularis oculi muscle of the upper lid. Triple injections were given in 227 treatments, of which 81% were successful. Mean duration of benefit was 8.5 weeks. Additional pretarsal injections were given in 183 treatment sessions. The number of successful treatments significantly increased, to 95% (P < 0.001), and the mean duration of benefit increased to 12.5 weeks (P < 0.001). Ptosis occurred significantly less often after pretarsal injections (P < 0.01). Patients with combined blepharospasm and involuntary levator palpebrae inhibition responded better to the pretarsal injection technique.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673963      PMCID: PMC486037          DOI: 10.1136/jnnp.59.3.309

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  17 in total

1.  Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia?

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-12       Impact factor: 10.154

2.  The levator aponeurosis. Attachments and their clinical significance.

Authors:  R L Anderson; C Beard
Journal:  Arch Ophthalmol       Date:  1977-08

Review 3.  Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects.

Authors:  E Tolosa; M J Martí
Journal:  Adv Neurol       Date:  1988

4.  Botulinum toxin in the management of blepharospasm.

Authors:  J J Dutton; E G Buckley
Journal:  Arch Neurol       Date:  1986-04

Review 5.  Management of facial spasm with Clostridium botulinum toxin, type A (Oculinum)

Authors:  A W Biglan; M May; R A Bowers
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1988-12

6.  Pathophysiology of blepharospasm and oromandibular dystonia.

Authors:  A Berardelli; J C Rothwell; B L Day; C D Marsden
Journal:  Brain       Date:  1985-09       Impact factor: 13.501

7.  Botulinum A toxin injection as a treatment for blepharospasm.

Authors:  A B Scott; R A Kennedy; H A Stubbs
Journal:  Arch Ophthalmol       Date:  1985-03

8.  Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients.

Authors:  J Jankovic; J Ford
Journal:  Ann Neurol       Date:  1983-04       Impact factor: 10.422

9.  Blepharospasm: a review of 264 patients.

Authors:  F Grandas; J Elston; N Quinn; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

10.  Distant effects of local injection of botulinum toxin.

Authors:  D J Lange; M F Brin; C L Warner; S Fahn; R E Lovelace
Journal:  Muscle Nerve       Date:  1987 Jul-Aug       Impact factor: 3.217

View more
  16 in total

1.  Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.

Authors:  P Roggenkämper; W H Jost; K Bihari; G Comes; S Grafe
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

2.  Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 3.  Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases.

Authors:  S Jitpimolmard; S Tiamkao; M Laopaiboon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-06       Impact factor: 10.154

Review 4.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

Review 5.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

6.  Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results.

Authors:  Dirk Dressler; Chrisanthi Karapantzou; Saskia Rohrbach; Simon Schneider; Rainer Laskawi
Journal:  J Neural Transm (Vienna)       Date:  2016-11-05       Impact factor: 3.575

7.  Botulinum toxin type A therapy for blepharospasm.

Authors:  Gonçalo S Duarte; Filipe B Rodrigues; Raquel E Marques; Mafalda Castelão; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19

Review 8.  Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.

Authors:  Wilhelm J Schulte-Mattler
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Primary blepharospasm: diagnosis and management.

Authors:  Giovanni Defazio; Paolo Livrea
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  The focal dystonias: current views and challenges for future research.

Authors:  H A Jinnah; Alfredo Berardelli; Cynthia Comella; Giovanni Defazio; Mahlon R Delong; Stewart Factor; Wendy R Galpern; Mark Hallett; Christy L Ludlow; Joel S Perlmutter; Ami R Rosen
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.